JP2009544318A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544318A5
JP2009544318A5 JP2009521850A JP2009521850A JP2009544318A5 JP 2009544318 A5 JP2009544318 A5 JP 2009544318A5 JP 2009521850 A JP2009521850 A JP 2009521850A JP 2009521850 A JP2009521850 A JP 2009521850A JP 2009544318 A5 JP2009544318 A5 JP 2009544318A5
Authority
JP
Japan
Prior art keywords
influenza virus
polypeptide
particle
virus
chimeric influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009521850A
Other languages
English (en)
Japanese (ja)
Other versions
JP5683811B2 (ja
JP2009544318A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/016900 external-priority patent/WO2008094197A2/en
Publication of JP2009544318A publication Critical patent/JP2009544318A/ja
Publication of JP2009544318A5 publication Critical patent/JP2009544318A5/ja
Application granted granted Critical
Publication of JP5683811B2 publication Critical patent/JP5683811B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009521850A 2006-07-27 2007-07-27 キメラインフルエンザウイルス様粒子 Expired - Fee Related JP5683811B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83420006P 2006-07-27 2006-07-27
US60/834,200 2006-07-27
US87892007P 2007-01-05 2007-01-05
US60/878,920 2007-01-05
PCT/US2007/016900 WO2008094197A2 (en) 2006-07-27 2007-07-27 Chimeric influenza virus-like particles

Publications (3)

Publication Number Publication Date
JP2009544318A JP2009544318A (ja) 2009-12-17
JP2009544318A5 true JP2009544318A5 (enExample) 2010-08-19
JP5683811B2 JP5683811B2 (ja) 2015-03-11

Family

ID=39674641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521850A Expired - Fee Related JP5683811B2 (ja) 2006-07-27 2007-07-27 キメラインフルエンザウイルス様粒子

Country Status (6)

Country Link
US (1) US9439959B2 (enExample)
EP (1) EP2044198A4 (enExample)
JP (1) JP5683811B2 (enExample)
AU (1) AU2007345768B2 (enExample)
CA (1) CA2659275C (enExample)
WO (1) WO2008094197A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044224A4 (en) * 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc CHIMERIC VIRUS TYPE PARTICLES
CA2683977C (en) 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
US20110262483A1 (en) * 2008-11-03 2011-10-27 Ligocyte Pharmaceuticals, Inc. Methods for isolating enveloped virus-based vlps free of infectious agents
AU2008364200B2 (en) * 2008-11-19 2016-01-28 Laboratorio Avi-Mex, S.A. De C.V. Recombinant inactivated viral vector vaccine
WO2010111586A2 (en) * 2009-03-27 2010-09-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Mucosal immunization
US9603919B2 (en) * 2009-03-31 2017-03-28 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
CN102414313B (zh) * 2009-05-01 2014-04-02 雷德生物科技股份公司 多基因载体编码的重组病毒样颗粒
WO2011003100A2 (en) 2009-07-02 2011-01-06 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
CN102753582A (zh) 2009-11-03 2012-10-24 莱戈赛特医药股份有限公司 嵌合RSV-F多肽、和慢病毒或α-反转录病毒GAG基VLP
WO2011057134A1 (en) 2009-11-05 2011-05-12 Novici Biotech Llc Generation of antigenic virus-like particles through protein-protein linkages
US20130028933A1 (en) * 2009-12-28 2013-01-31 Ligocyte Pharmaceuticals, Inc. Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions
HUE037157T2 (hu) * 2010-01-21 2018-08-28 Univ Arkansas Vakcinavektorok, és eljárások immunválaszok fokozására
JP5942296B2 (ja) * 2010-03-29 2016-06-29 サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィクＣｅｎｔｒｅ Ｎａｔｉｏｎａｌ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｓｃｉｅｎｔｉｆｉｑｕｅ 少なくとも１つのｃｘｘｃモチーフを含むポリペプチドと異種抗原とを含む医薬組成物、及びその使用
EP2640405A4 (en) 2010-09-21 2015-04-15 Massachusetts Inst Technology HA-POLYPEPTIDES ADAPTED TO HUMANS, VACCINES THEREOF AND INFLUENZA TREATMENT THEREWITH
SG10201709806VA (en) 2010-10-04 2017-12-28 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
KR101745472B1 (ko) * 2015-04-15 2017-06-12 대한민국 조류인플루엔자 바이러스의 세포 감염을 저해하는 물질을 선별하는 방법
TWI758288B (zh) 2016-05-03 2022-03-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
EP3464327A1 (en) 2016-06-03 2019-04-10 Sanofi Pasteur Inc. Modification of engineered influenza hemagglutinin polypeptides
WO2021085650A1 (ja) * 2019-10-31 2021-05-06 有限会社根路銘生物資源研究所 ワクチン
CN113827715B (zh) * 2020-06-23 2024-07-05 普莱柯生物工程股份有限公司 一种抗h7亚型和h5亚型禽流感病毒的疫苗组合物、及其制备方法和应用
CN113264989A (zh) * 2021-05-17 2021-08-17 吉林大学 一种h9n2亚型禽流感嵌合病毒样颗粒制备方法及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485729B1 (en) * 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
AU736318B2 (en) 1996-11-26 2001-07-26 Nventa Biopharmaceuticals Corporation Immune responses using compositions containing stress proteins
US6099847A (en) 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
CA2360347C (en) * 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
DE60136811D1 (de) 2000-06-23 2009-01-15 Us Gov Health & Human Serv Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren
BRPI0111830B8 (pt) 2000-06-23 2021-05-25 American Cyanamid Co método de produção de partículas semelhantes ao vírus da influenza (vlps), vlps da influenza, vlps quiméricas, composições imunogênica e farmacêutica, e, usos de vlps da influenza e de vlps quiméricas
DE60127675T2 (de) 2000-06-28 2007-12-27 Fuji Nihon Seito Corp. Neuartige insulin synthase und verfahren zur herstellung von insulin durch anwendung derselben
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
US20030049607A1 (en) 2001-03-12 2003-03-13 Tsvika Greener Compositions and methods for the modulation of viral maturation
WO2003004657A1 (en) 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
GB0202569D0 (en) * 2002-02-04 2002-03-20 Oxford Biomedica Ltd Delivery means
SI1506223T1 (sl) 2002-05-16 2006-04-30 Bavarian Nordic As Fuzijski protein HIV regulatornih/akcesorskih proteinov
CA2486282C (en) * 2002-05-17 2012-04-10 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
US20060088909A1 (en) * 2002-05-17 2006-04-27 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
PL375306A1 (en) 2002-06-20 2005-11-28 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
GB0226722D0 (en) 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US6910730B2 (en) * 2002-12-25 2005-06-28 Shiroki Corporation Mounting device for mounting a cable-operated window regulator
US8080255B2 (en) * 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8574590B2 (en) * 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
US7404963B2 (en) * 2004-10-01 2008-07-29 The University Of South Florida Flagellin-based adjuvants and vaccines
TWI488968B (zh) * 2005-10-18 2015-06-21 Novavax Inc 功能性流行性感冒類病毒顆粒（ＶＬＰｓ）
US8437251B2 (en) 2005-12-22 2013-05-07 Qualcomm Incorporated Methods and apparatus for communicating transmission backlog information
EP2044224A4 (en) * 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc CHIMERIC VIRUS TYPE PARTICLES
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
AU2009279456B2 (en) * 2008-08-08 2015-02-05 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity

Similar Documents

Publication Publication Date Title
JP2009544318A5 (enExample)
JP7250878B2 (ja) 新規多価ナノ粒子に基づくワクチン
Panahi et al. An overview on the treatments and prevention against COVID-19
Tornesello et al. Virus-like particles as preventive and therapeutic cancer vaccines
Soraci et al. COVID-19 vaccines: current and future perspectives
RU2609645C2 (ru) Экспрессионные системы
Lundstrom Replicon RNA viral vectors as vaccines
Altenburg et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases
Lundstrom Alphavirus-based vaccines
Buonaguro et al. Developments in virus-like particle-based vaccines for infectious diseases and cancer
JP2010535026A5 (enExample)
JP2016534034A5 (enExample)
JP2020517635A5 (enExample)
Wang et al. Protective efficacy of the conserved NP, PB1, and M1 proteins as immunogens in DNA-and vaccinia virus-based universal influenza A virus vaccines in mice
JP2016513115A5 (enExample)
JP2016516723A5 (enExample)
AU2018322831A9 (en) A vaccine for use in the prophylaxis and/or treatment of a disease
JP2015506705A5 (enExample)
Lee et al. Nucleoprotein vaccine induces cross-protective cytotoxic T lymphocytes against both lineages of influenza B virus
JP2008056679A5 (enExample)
MX2020000221A (es) Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas.
JP2013510091A5 (enExample)
RU2015135890A (ru) Композиция вакцины
Spunde et al. Recombinant viral vectors for therapeutic programming of tumour microenvironment: Advantages and limitations
AU2017264901A1 (en) Combination prime: boost therapy